Tim Attebery Joins CorVista Health’s Board of Directors

CorVista Health Inc has elected Dr. Tim Attebery to its Board of Directors.
 
As the company approaches commercialization, CorVista Health recognizes the importance of enhancing its Board of Directors with specialized expertise in the field of cardiovascular care. Attebery’s significant contributions in reshaping the model of U.S. cardiovascular care delivery through his leadership at organizations such as the American College of Cardiology and Cardiovascular Associates of America make him a highly valued addition to the board. “Our shareholders, along with the leadership team of CorVista Health, are thrilled to have Tim join our Board of Directors,” CorVista Health President Don Crawford said. “His insights and expertise will enrich our board, and I am confident that his vast experience in healthcare and leadership will be instrumental in driving our future growth and development.”

Attebery is CEO of Cardiovascular Associates of America (CVAUSA). He and Webster Equity Partners founded CVAUSA in December 2021 with the intent to partner with leading cardiovascular group practices in the United States, with a common goal of providing quality care and an excellent patient experience while reducing overall care costs for those with heart and vascular disease. At CVAUSA, Attebery has created a business model that enables cardiovascular specialists to retain autonomy augmented by sharing best practices, executive management support, and financial support for major projects and expansion. As of June 2023, CVAUSA had 19 partner groups with more than 325 cardiovascular specialists operating in eight states. 
 
As a board member, Attebery will provide further guidance and governance, drawing from his deep understanding of the cardiovascular healthcare space. His involvement will additionally support CorVista Health as it enters the next phase of growth following U.S. Food and Drug Administration (FDA) Breakthrough Designation for its pulmonary hypertension focused device.
 
“I believe CorVista Health can transform the way cardiovascular disease is diagnosed, particularly in underserved geographies and populations with the greatest need,” Attebery stated. “Advancements in healthcare are essential to help improve the diagnosis of cardiovascular patients especially in rural areas, and CorVista’s innovative solution has the potential to make a tremendous impact to our healthcare system.”

The CorVista System is a non-invasive point-of-care solution that is intended to synchronously collect and apply machine learning to a patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting or exercise. Within minutes of the test, the CorVista Analysis is available in a secure web portal to aid physicians in rapidly diagnosing and treating patients with suspected cardiovascular disease, answering important clinical questions to guide better treatment decisions. CorVista System is an investigational device limited by federal law to investigational use. 
 
CorVista Health is applying machine learning to develop a novel cardiac diagnostic platform, CorVista System, with the aim of transforming cardiovascular care and the patient experience. CorVista Health is dedicated to addressing the FDA’s call to action for leveraging health technologies to advance health equity, as presented by FDA Commissioner Dr. Robert Califf. The CorVista System has the potential to enable more equitable care by providing access to immediately actionable, high-quality cardiovascular status results in low-resource settings, where access to capital-intensive equipment and the qualified specialists needed to operate them may not be available.